Arrowhead Pharmaceuticals, Inc. (LON:0HI3)

Market Cap	3.95B
Revenue (ttm)	418.22M
Net Income (ttm)	-108.33M
Shares Out	n/a
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	473
Average Volume	3,011
Open	38.00
Previous Close	37.79
Day's Range	36.93 - 38.00
52-Week Range	9.70 - 40.24
Beta	1.14
RSI	59.79
Earnings Date	Nov 26, 2025

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 609
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HI3

Financial Performance

In 2024, Arrowhead Pharmaceuticals's revenue was $3.55 million, a decrease of -98.52% compared to the previous year's $240.74 million. Losses were -$599.49 million, 192.0% more than in 2023.

Financial numbers in USD